Human immunodeficiency virus type 1 proteins (HIV-1 proteins) (HIV-1 proteins)

Human immunodeficiency virus type 1 (HIV-1) proteins are the primary targets for vaccine development, serving as antigens to elicit protective immune responses. These proteins are encoded by the viral genome and include structural proteins (Gag, Pol, and Env), regulatory proteins (Tat and Rev), and accessory proteins (Nef, Vif, Vpr, and Vpu) [1, 11]. The envelope glycoprotein (Env), composed of gp120 and gp41 subunits, is the sole viral protein on the surface and the primary target for neutralizing antibodies that block viral entry [1, 6]. Internal proteins such as Gag (capsid) and Pol (enzymes like reverse transcriptase and integrase) are critical targets for cell-mediated immunity, where cytotoxic T lymphocytes (CTLs) recognize and eliminate infected cells [2, 3]. Vaccines targeting these antigens utilize various platforms, including mRNA, viral vectors, and recombinant proteins, to induce both humoral and cellular defenses [6, 13]. Despite their potential, these antigens present significant challenges due to the virus's high mutation rate, extensive glycosylation of Env, and the rapid establishment of latent viral reservoirs [6, 7]. Effective immunization strategies aim to generate broadly neutralizing antibodies (bNAbs) that can overcome the extreme genetic diversity of circulating HIV-1 strains [10, 12].

Other names

HIV-1 antigensHIV-1 vaccine antigensHIV-1 polyproteinsGag-Pol-Env antigensHIV-1 structural proteinsHIV-1 regulatory proteinsHIV-1 accessory proteins

Induction of neutralizing antibodies to block viral entry and fusion, stimulation of cytotoxic T-lymphocyte (CTL) responses to eliminate virally infected cells, and inhibition of viral replication through targeted immune recognition of regulatory and accessory proteins.